ChromaDex (NASDAQ:CDXC) Share Price Passes Above 200 Day Moving Average of $1.63

ChromaDex Co. (NASDAQ:CDXC – Get Rating)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.63 and traded as high as $1.91. ChromaDex shares last traded at $1.90, with a volume of 78,946 shares traded.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CDXC. StockNews.com raised shares of ChromaDex from a “hold” rating to a “buy” rating in a report on Friday, November 4th. B. Riley reduced their price objective on shares of ChromaDex from $2.40 to $2.10 in a report on Thursday, November 3rd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $5.40.

ChromaDex Stock Performance

The firm has a market cap of $141.12 million, a price-to-earnings ratio of -6.53 and a beta of 1.66. The business’s 50-day moving average is $1.72 and its 200-day moving average is $1.63.

ChromaDex (NASDAQ:CDXC – Get Rating) last announced its earnings results on Wednesday, November 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The business had revenue of $17.06 million during the quarter, compared to analysts’ expectations of $18.69 million. ChromaDex had a negative net margin of 29.71% and a negative return on equity of 90.73%. Equities research analysts expect that ChromaDex Co. will post -0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On ChromaDex

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Gabelli Funds LLC acquired a new stake in ChromaDex in the 3rd quarter valued at about $34,000. Oppenheimer & Co. Inc. increased its position in ChromaDex by 127.3% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 39,110 shares of the company’s stock valued at $65,000 after acquiring an additional 21,900 shares in the last quarter. Virtu Financial LLC acquired a new stake in ChromaDex in the 2nd quarter valued at about $76,000. XTX Topco Ltd acquired a new stake in ChromaDex in the 1st quarter valued at about $76,000. Finally, Royal Bank of Canada bought a new position in shares of ChromaDex in the 3rd quarter valued at about $93,000. Institutional investors and hedge funds own 42.81% of the company’s stock.

ChromaDex Company Profile

(Get Rating)

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.